Clinical trials: Psychosis; Acute
Schizophrenia, Schizoaffective Disorder
SUCCEED Africa: Support, Comprehensive Care and Empowerment of People With Psychosocial Disabilities
Although psychotic disorders typically affect less than 1% of the population, they are a significant cause of disability worldwide.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizotypal Disorder, Acute and Transient Psychotic Disorder
- Trial name
- SUCCEED (NCT06007105)
- Testing
- SUCCEED Community-Based Intervention
- Where
- 4 sites in Malawi, Nigeria and 2 more
- Volunteers
- 425 people
- Sponsor
- London School of Hygiene and Tropical Medicine
Psychosis
Enhancing Mental Health Outcomes for Patients With Psychosis in Malawi Through Community-based Rehabilitation
The overall aim of the proposed study is to determine the feasibility, acceptability, fidelity, and preliminary effectiveness of the adapted nurse-led, community-based rehabilitation treatment model for community-dwelling…
- Trial name
- ENHANCE (NCT06080477)
- Testing
- Enhanced Usual Care, Adapted ENHANCE Intervention
- Where
- Malawi
- Volunteers
- 178 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Schizophrenia
Non-interventional (NI) Study to Observe Efficacy and Usage of Quetiapine in Acute Episodes of Schizophrenia and as Maintenance Therapy Following Standard Clinical Practice in Croatia
Observational, non-comparative, epidemiological study to collect and analyse real life data on schizophrenic patients receiving quetiapine according to the standard medical practice in Croatia.
- Trial name
- NCT00981123
- Where
- 18 sites in Croatia
- Volunteers
- 500 people
- Sponsor
- AstraZeneca
Affective Psychosis, Bipolar, Bipolar Disorder
A Study to Evaluate the Efficacy and Safety of Adjustable Doses of Extended-release (ER) Paliperidone Compared With Placebo, in Combination With Lithium or Valproate, to Treat Manic and Mixed Episodes in Patients With Bipolar I Disorder
The purpose of this study is to evaluate the effectiveness and safety over a 6-week period of paliperidone ER compared with placebo in treating subjects with Bipolar I Disorder who are experiencing a manic or mixed episode while…
- Conditions
- Affective Psychosis, Bipolar, Bipolar Disorder, Mania
- Trial name
- NCT00309686
- Testing
- Paliperidone ER
- Volunteers
- 300 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
Efficacy and Safety of Asenapine With Placebo and Olanzapine (41022)(P05947)
Schizophrenia is a brain disease. The primary features of schizophrenia are characterized by Positive symptoms (symptoms that should not be there, inability to think clearly, to distinguish reality from fantasy i.e., hearing…
- Trial name
- NCT00151424
- Testing
- asenapine, Olanzapine
- Volunteers
- 277 people
- Sponsor
- Organon and Co
Psychotic Disorders
A Study Based on the French National Health Insurance Database in Participants With Psychotic Disorders
The primary purpose of the study is to compare therapy with antipsychotic medication (antipsychotic monotherapy or antipsychotic combination) versus no antipsychotic medication, and antipsychotic monotherapy versus antipsychotic…
- Trial name
- NCT05633108
- Testing
- No Intervention
- Where
- United Kingdom
- Volunteers
- 579,728 people
- Sponsor
- Eisai Co., Ltd.
Schizophrenia
Does Acute Oxytocin Administration Enhance Social Cognition in Individuals With Schizophrenia?
Individuals with schizophrenia have been found to have deficits in social cognition, which is defined as the functions that are engaged during social interactions.
- Trial name
- NCT01312272
- Testing
- Oxytocin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- VA Greater Los Angeles Healthcare System
Schizophrenia, Psychosis
Quetiapine Extended Release (XR) for the Management of Psychotic Aggression or Agitation in Adult Acute Psychiatry
This study is a multi-site study examining the use of Quetiapine XR for psychotic aggression in an acute psychiatric setting. The study aims to demonstrate that management with Quetiapine XR significantly reduces aggressive…
- Trial name
- NCT00986167
- Testing
- Quetiapine XR
- Where
- 2 sites in Australia
- Volunteers
- 72 people
- Sponsor
- Bayside Health
Post Acute COVID-19 Syndrome
Cognitive-behavioral Therapy for Mental Disorder in COVID-19 Survivors
The consequences of the Intensive Care Unit and the Covid-19 disease are still uncertain. However, many studies are bringing out often psychological and dramatic consequences for many COVID-survivor patients.
- Trial name
- LONGCOVID (NCT05815693)
- Testing
- mindfulness-based stress reduction (MBSR) and cognitive behavioral therapy (CBT)
- Where
- Italy
- Volunteers
- 140 people
- Sponsor
- Azienda Socio Sanitaria Territoriale di Lecco
Schizophrenia, Schizoaffective Disorder
A Study of the Efficacy and Safety of Ziprasidone for the Treatment of Acute Exacerbation of Schizophrenia or Schizoaffective Disorder
This study was conducted to examine the efficacy and tolerability of ziprasidone intramuscular (IM), and to assess the effect of switching from IM to oral ziprasidone for the treatment of acute exacerbation of schizophrenia and…
- Trial name
- NCT00650429
- Testing
- Ziprasidone
- Where
- 4 sites in Mexico
- Volunteers
- 28 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Psychosis, Schizophrenia
Motivational Interviewing for Patients With Acute Psychosis
Psychotic disorders are associated with high levels of distress, limitations in quality of life, and a high risk of chronification for those affected.
- Trial name
- MIA (NCT05911529)
- Testing
- Motivational Interviewing, Supportive conversations
- Where
- Switzerland
- Volunteers
- 28 people
- Sponsor
- Psychiatric University Hospital, Zurich
Molecular Mechanisms of Pharmacological Action, Depression
Citalopram and Self Emotional Processing
This study is investigating the effect of an acute dose of citalopram on emotional processing about the self. Using a parallel-group double-blind design, participants will be randomised to receive either an acute dose of…
- Conditions
- Molecular Mechanisms of Pharmacological Action, Depression, Depressive Disorder, Mental Disorder
- Trial name
- NCT04169230
- Testing
- Citalopram
- Where
- United Kingdom
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Schizophrenia
Efficacy and Safety of Asenapine With Placebo and Haloperidol (41023)(P05926)(COMPLETED)
Schizophrenia is a brain disease. The primary features of schizophrenia are characterized by Positive symptoms (symptoms that should not be there, inability to think clearly, to distinguish reality from fantasy i.e., hearing…
- Trial name
- NCT00156104
- Testing
- Asenapine, Haloperidol
- Volunteers
- 460 people
- Sponsor
- Organon and Co
Depression, Bipolar Disorder
Peer Support Experience for Patients Discharged From Acute Psychiatric Care
The aim of the project is to conduct a four arm randomized controlled pilot trial to evaluate the effectiveness of an innovative peer support program that incorporates leadership training, mentorship, recognition, reward systems…
- Conditions
- Depression, Bipolar Disorder, Schizophrenia
- Trial name
- NCT03404882
- Testing
- Supportive/reminder text messaging plus peer support, Supportive/reminder text messaging, Peer support only
- Where
- 5 sites in Canada
- Volunteers
- 182 people
- Sponsor
- University of Alberta
Schizophrenia
Observe Real-life Allocation of Atypical Antipsychotics in the Acute Inpatient Management of Schizophrenia
The primary objective of this Non- Interventional Study (NIS) is to describe the use of atypical antipsychotics in subjects with Schizophrenia during the hospitalisation due to acute psychotic episode by evaluation of drug, dose…
- Trial name
- RECONNECT-S (NCT01544608)
- Where
- 7 sites in Egypt, Saudi Arabia and 1 more
- Volunteers
- 1,076 people
- Sponsor
- AstraZeneca
Schizophrenia
Brexpiprazole in Patients With Acute Schizophrenia
To determine the efficacy and safety of brexpiprazole for the treatment of adults experiencing an acute episode of schizophrenia.
- Trial name
- NCT01810380
- Testing
- Brexpiprazole, Quetiapine extended release
- Where
- United States
- Volunteers
- 468 people
- Sponsor
- H. Lundbeck A/S
Schizophrenia
A Study of Flexibly Dosed Paliperidone Extended Release Tablets in Participants With Schizophrenia
The purpose of this study is to evaluate the effectiveness of paliperidone extended-release (ER; designed to slowly release a drug in the body over an extended period of time) tablets in participants with schizophrenia…
- Trial name
- NCT01541371
- Testing
- Paliperidone ER
- Volunteers
- 405 people
- Sponsor
- Xian-Janssen Pharmaceutical Ltd.
Schizophrenia
Long-term Study of Cariprazine in Patients With Schizophrenia
The objective of this study is to evaluate the long-term safety, tolerability, and pharmacokinetics of cariprazine in patients with schizophrenia.
- Trial name
- NCT01104792
- Testing
- Cariprazine
- Where
- 86 sites in United States, Colombia and 4 more
- Volunteers
- 752 people
- Sponsor
- Forest Laboratories
Mental Disorder
Testing the Effectiveness of an Evening Blue-depleted Light Environment in an Acute Psychiatric Ward
There is increasing recognition of the need to stabilize sleep-wake cycles in individuals with major mental disorders. As such, clinicians and researchers advocate for the use of interventions targeted at sleep and circadian…
- Trial name
- NCT03788993
- Testing
- Blue-depleted evening light condition, Normal light condition
- Where
- Norway
- Volunteers
- 475 people
- Sponsor
- St. Olavs Hospital
Major Depressive Disorder
Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder
The purpose of this study is to determine the effectiveness and safety of vortioxetine, once daily (QD), in patients with Major Depressive Disorder.
- Trial name
- NCT00735709
- Testing
- Vortioxetine
- Where
- 48 sites in Australia, Czechia and 13 more
- Volunteers
- 560 people
- Sponsor
- Takeda